To explore whether this elevated expression level of NAT10 has biological significance in the development of bladder cancer, we treated BBN‐induced BLCA mice with the NAT10‐specific inhibitor Remodelin for 4 weeks. The gene discussed is NAT10; the disease is bladder transitional cell carcinoma.